Results 101 to 110 of about 7,990,092 (312)

Clinical trials on trial [PDF]

European Journal of Hospital Pharmacy, 2012
It has been 3 years since I wrote an editorial on the topic of uncertainty around new cancer treatments (issue 4 of volume 2009). Has this field progressed in 3 years? I think the answer is both yes and no. Yes because we now have a clearer picture of why cancer drugs can sometimes act differently (usually worse) in real life situations than they seem ...
openaire   +2 more sources

Decoding the dynamic extracellular matrix in cancer—3D models and bioscaffolds rewire the rules of tumor progression

FEBS Letters, EarlyView.
Cancer progression is regulated by the dynamic matrix code of the tumor microenvironment, which influences cellular behavior and disease development. Importantly, matrix remodeling in three‐dimensional cancer models more accurately reflects in vivo conditions compared to conventional two‐dimensional systems.
Sylvia Mangani, Konstantinos Spanopoulos, Zoi Piperigkou, Nikos K. Karamanos   +3 more
wiley   +1 more source

Three-outcome designs for external pilot trials with progression criteria

BMC Medical Research Methodology
Background Whether or not to progress from a pilot study to a definitive trial is often guided by pre-specified quantitative progression criteria with three possible outcomes.
Duncan T. Wilson, Eleanor Hudson, Sarah Brown   +2 more
doaj   +1 more source

Experience and Challenges from Clinical Trials with Malaria Vaccines in Africa. [PDF]

, 2013
Malaria vaccines are considered amongst the most important modalities for potential elimination of malaria disease and transmission. Research and development in this field has been an area of intense effort by many groups over the last few decades ...
Mpina, Maxmillian, Abdulla, Salim, Shekalaghe, Seif, Tanner, M., Salim Abdulla, Mpina, M., Seif Shekalaghe, Shekalaghe, S., Marcel Tanner, Salim, N., Kafuruki, Shubis, Mzee, T., Tutu Mzee, Abdulla, S., Grace Mwangoka, Mwangoka, G., Tanner, Marcel, Beverly Msambichaka, Mzee, Tutu, Ogutu, Bernhards, Mwangoka, Grace, Nahya Salim, Msambichaka, Beverly, Salim, Nahya, Shubis Kafuruki, Ogutu, B., Kafuruki, S., Bernhards Ogutu, Maxmillian Mpina, Msambichaka, B.   +29 more
core   +1 more source

Conserved binding mode but diverse interfaces of MreC‐PBP2 interactions

FEBS Letters, EarlyView.
The crystal structure of abMreC reveals a conserved two β‐barrel architecture and provides structural insights into its role within the bacterial elongasome. The abMreC–abPBP2 complex model identifies the molecular basis of MreC‐mediated PBP2 recognition, contributing to the regulation of peptidoglycan synthesis.
Hyunseok Jang, Hyo Been Jin, Chang Min Kim, So Yeon Lee, Hyun Ho Park   +4 more
wiley   +1 more source

Practical methods for incorporating summary time-to-event data into meta-analysis: updated guidance

Systematic Reviews
Our previous guide to estimating hazard ratios (HRs) from published summary (aggregate) data has become very widely used, but many still have difficulties knowing when and how to apply the methods.
Jayne F. Tierney, Sarah Burdett, David J. Fisher   +2 more
doaj   +1 more source

Microbiome‐blood–brain barrier interactions in aging — mechanisms and therapeutic potential

FEBS Letters, EarlyView.
Aging reshapes the gut microbiome (↓SCFA‐producing commensals; ↑pro‐inflammatory outputs), shifting circulating metabolites (↓SCFAs; ↑LPS, ↑TMAO, ↑PAA) that act at the BBB to increase nonspecific transcytosis, alter transport, and promote astrocyte reactivity, heightening brain vulnerability.
Daniel Cuervo‐Zanatta, Hari Baskar Balasubramanian, Amir Pasokh, Marietta Zille   +3 more
wiley   +1 more source

An epithelial GPR35 isoform supports tumor‐associated transcriptional and metabolic phenotypes

FEBS Letters, EarlyView.
GPR35 generates two functionally distinct isoforms with previously unresolved roles. GPR35‐short mediates immune‐cell chemotaxis, while GPR35‐long is enriched in colorectal cancer epithelium, where it supports increased metabolism, proliferation, and tumor‐associated transcriptional programs.
Jørgen D. Rønneberg, Martine Hjeltnes, Josephine Krieger, Joshua E. Elias, Maria Stensland, Kristian Holm, Xiaojun Jiang, Chuki Khangsar, Tuula A. Nyman, Arthur Kaser, Johannes R. Hov, Tom H. Karlsen, Nicole C. Kaneider, Frode L. Jahnsen, Georg Schneditz   +14 more
wiley   +1 more source

Endpoint comparison for bone mineral density measurements in North Central Cancer Treatment Group cancer clinical trials N02C1 and N03CC (Alliance)

, 2015
Bone mineral density (BMD) measurement can vary depending upon anatomical site, machine, and normative values used. This analysis compared different BMD endpoints in two clinical trials. Trial results differed across endpoints.
Alliance Clinical Trials Oncology
core   +1 more source

Structure‐forward targeting of claudins with synthetic binders

FEBS Letters, EarlyView.
Claudins form the paracellular barriers between epithelial and endothelial tissues at tight junctions and are targets for molecular binders with the goal of modulating barrier permeability. Claudin‐binding molecules are relevant in drug delivery or in altering claudin interactions with disease‐causing proteins.
Alex J. Vecchio
wiley   +1 more source